Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.43 |
| ▸ | ACE | P12821 | 5/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492387 | 1.00 | DPP4 (0.43) | DPP4ACESPHK2SPHK1CA12 | |
| SCHEMBL475439 | 1.00 | DPP4 (0.43) | DPP4ACESPHK2SPHK1CA12 | |
| SCHEMBL6062398 | 0.94 | CA12 (0.41) | DPP4ACESPHK2SPHK1CA12 | |
| SCHEMBL2679657 | 0.94 | CA12 (0.41) | DPP4ACESPHK2SPHK1CA12 | |
| SCHEMBL3073855 | 0.94 | CA12 (0.41) | DPP4ACESPHK2SPHK1CA12 | |
| SCHEMBL11882083 | 0.92 | CA12 (0.40) | DPP4SPHK2SPHK1CA12CA1 | |
| SCHEMBL1074840 | 0.86 | DPP4 (0.33) | DPP4SPHK2SPHK1 | |
| SCHEMBL1074843 | 0.86 | DPP4 (0.33) | DPP4SPHK2SPHK1 | |
| SCHEMBL26112742 | 0.86 | DPP4 (0.33) | DPP4SPHK2SPHK1 | |
| SCHEMBL8591233 | 0.84 | HTT (0.45) | DPP4ACESPHK2SPHK1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023249563-A1 | COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023248871-A1 | HETEROARYL COMPOUND AND PEST CONTROL AGENT | 日本曹達株式会社 | 2023-12-28 | — | — | WO | disclosed |
| CN-115403652-A | Preparation method of obitasvir | 心远(广州)药物研究有限公司 | 2022-11-29 | — | — | CN | disclosed |
| US-20210292339-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2021-09-23 | — | — | US | disclosed |
| CN-108026105-B | TGF-beta receptor antagonists | 百时美施贵宝公司 | 2020-10-16 | — | — | CN | disclosed |
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-08-13 | — | — | US | disclosed |
| EP-3668503-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019035899-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190055264-A1 | Macrocyclic MCL-1 inhibitors and methods of use | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-02-21 | — | — | US | disclosed |
| EP-1960396-B1 | CARBAMATE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE INC (US) | 2009-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292339-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | DPP4 4811/4885ACE 4689/4885SPHK2 2631/4885 |
| US-20190055264-A1 | Macrocyclic MCL-1 inhibitors and methods of use | MCL1, BCL2A1, BCL2L10 | DPP4 4811/4885ACE 4689/4885SPHK2 2631/4885 |
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | DPP4 4811/4885ACE 4689/4885SPHK2 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.